LLY
911.65
+0.96%↑
JNJ
235.8
+0.14%↑
ABBV
205.01
+0.38%↑
NVS
147.58
+1.16%↑
AZN
184.25
+0.48%↑
LLY
911.65
+0.96%↑
JNJ
235.8
+0.14%↑
ABBV
205.01
+0.38%↑
NVS
147.58
+1.16%↑
AZN
184.25
+0.48%↑
LLY
911.65
+0.96%↑
JNJ
235.8
+0.14%↑
ABBV
205.01
+0.38%↑
NVS
147.58
+1.16%↑
AZN
184.25
+0.48%↑
LLY
911.65
+0.96%↑
JNJ
235.8
+0.14%↑
ABBV
205.01
+0.38%↑
NVS
147.58
+1.16%↑
AZN
184.25
+0.48%↑
LLY
911.65
+0.96%↑
JNJ
235.8
+0.14%↑
ABBV
205.01
+0.38%↑
NVS
147.58
+1.16%↑
AZN
184.25
+0.48%↑
24h
Corrente
Minimo
6.52
Massimo
7.5
Entrata | -69M -102M |
|---|---|
Vendite | -10M 34M |
EPS | -5.69 |
Margine di Profitto | -299.886 |
Dipendenti | 228 |
EBITDA | 4.7M -18M |
Raccomandazioni | Fortemente da comprare |
|---|---|
Previsioni per 12 mesi | +192.79% upside |
Capitalizzazione di Mercato | -267K 157M |
|---|---|
Apertura precedente | 19.09 |
Chiusura precedente | 6.56 |
By Acuity
67%
33%
303 / 350 Classifica in Healthcare
By Trading Central
Fiducia
Bullish Evidence
5.9501 / 7.66 Supporto e resistenza
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
23 mar 2026, 23:47 UTC
Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update
DJ
LeggI
23 mar 2026, 22:55 UTC
Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion
DJ
LeggI
23 mar 2026, 21:51 UTC
Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update
DJ
LeggI
23 mar 2026, 23:59 UTC
Global Equities Roundup: Market Talk
DJ
LeggI
23 mar 2026, 23:59 UTC
Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk
DJ
LeggI
23 mar 2026, 23:50 UTC
Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk
DJ
LeggI
23 mar 2026, 23:37 UTC
Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk
DJ
LeggI
23 mar 2026, 22:42 UTC
Global Equities Roundup: Market Talk
DJ
LeggI
23 mar 2026, 22:42 UTC
Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk
DJ
LeggI
23 mar 2026, 22:40 UTC
Gilead Sciences to Buy Ouro Medicines for Up to $2.18B
DJ
LeggI
23 mar 2026, 22:23 UTC
Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk
DJ
LeggI
23 mar 2026, 22:22 UTC
Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease
DJ
LeggI
23 mar 2026, 22:21 UTC
Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales
DJ
LeggI
23 mar 2026, 22:21 UTC
Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China
DJ
LeggI
23 mar 2026, 22:20 UTC
Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD
DJ
LeggI
23 mar 2026, 22:20 UTC
Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD
DJ
LeggI
23 mar 2026, 22:19 UTC
Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders
DJ
LeggI
23 mar 2026, 22:19 UTC
Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets
DJ
LeggI
23 mar 2026, 22:18 UTC
Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD
DJ
LeggI
23 mar 2026, 22:15 UTC
Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD
DJ
LeggI
23 mar 2026, 22:08 UTC
Ebos Needs to Reset Its Gearing Targets -- Market Talk
DJ
LeggI
23 mar 2026, 21:42 UTC
Global Forex and Fixed Income Roundup: Market Talk
DJ
LeggI
23 mar 2026, 21:42 UTC
RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk
DJ
LeggI
23 mar 2026, 21:32 UTC
WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK
DJ
LeggI
23 mar 2026, 21:32 UTC
WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK
DJ
LeggI
23 mar 2026, 21:32 UTC
WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK
DJ
LeggI
23 mar 2026, 21:10 UTC
Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com
DJ
LeggI
23 mar 2026, 20:50 UTC
Tech, Media & Telecom Roundup: Market Talk
DJ
LeggI
23 mar 2026, 20:50 UTC
Health Care Roundup: Market Talk
DJ
LeggI
23 mar 2026, 20:50 UTC
Basic Materials Roundup: Market Talk
DJ
LeggI
Modifica del prezzo
By TipRanks
Previsioni per 12 mesi
Media 19.5 USD 192.79%
Alto 28 USD
Basso 12 USD
Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Karyopharm Therapeutics Inc - Dist negli ultimi 3 mesi.
By TipRanks
Fortemente da comprare
5 ratings
5
Acquista
0
Mantieni
0
Vendi
Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Karyopharm Therapeutics Inc - Dist negli ultimi 3 mesi.
By Trading Central
A breve termine
Bullish Evidence
Recent bullish events outweigh bearish events.
A termine intermedio
Strong Bearish Evidence
All events are bearish.
A lungo termine
No Evidence
There are no events.
By Acuity
Notizie sul Sentiment di mercato
Prove ribassiste
Volatilità
Sotto la media
Volume delle notizie (RCV)
Sotto la media
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$